Repurposing Empagliflozin for Duchenne Muscular Dystrophy-Associated Cardiomyopathy: Protocol for a Pharmacokinetics, Safety and Proof-of-Concept Trial in Children.

Lava SAG, Laurence C, Mallory J, Della Pasqua O, Di Deo A, Villa C, Lang S, Quail M, Burch M

Open source

DOI
10.1007/s40119-026-00456-6
Published
2026 Sep
Container
Cardiology and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40119-026-00456-6,
  title = {Repurposing Empagliflozin for Duchenne Muscular Dystrophy-Associated Cardiomyopathy: Protocol for a Pharmacokinetics, Safety and Proof-of-Concept Trial in Children.},
  author = {Lava SAG and Laurence C and Mallory J and Della Pasqua O and Di Deo A and Villa C and Lang S and Quail M and Burch M},
  year = {2026},
  journal = {Cardiology and therapy},
  doi = {10.1007/s40119-026-00456-6},
  url = {https://doi.org/10.1007/s40119-026-00456-6}
}

RIS

TY  - JOUR
TI  - Repurposing Empagliflozin for Duchenne Muscular Dystrophy-Associated Cardiomyopathy: Protocol for a Pharmacokinetics, Safety and Proof-of-Concept Trial in Children.
AU  - Lava SAG
AU  - Laurence C
AU  - Mallory J
AU  - Della Pasqua O
AU  - Di Deo A
AU  - Villa C
AU  - Lang S
AU  - Quail M
AU  - Burch M
PY  - 2026
JO  - Cardiology and therapy
DO  - 10.1007/s40119-026-00456-6
UR  - https://doi.org/10.1007/s40119-026-00456-6
ER  - 

APA

SAG, L., C, L., J, M., O, D. P., A, D. D., C, V., S, L., M, Q., & M, B. (2026). Repurposing Empagliflozin for Duchenne Muscular Dystrophy-Associated Cardiomyopathy: Protocol for a Pharmacokinetics, Safety and Proof-of-Concept Trial in Children.. Cardiology and therapy. https://doi.org/10.1007/s40119-026-00456-6

Source records